

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Rigdon Lentz

Serial No.: 09/709,045

Art Unit: 1647

Filed: November 10, 2000

Examiner: Lorraine Spector

For: *METHOD AND SYSTEM TO REMOVE CYTOKINE INHIBITOR IN PATIENTS*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. § 1.97, Applicant submits a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449 and copies of the five (5) documents cited therein. Also enclosed herewith is a copy of a translation of a Japanese Official Action dated January 24, 2008 from Japanese Patent Application Number 2004-148356 which is related to the present application and provides a concise explanation of the relevance of the publication marked with an asterisk below, in accordance with 37 C.F.R. § 1.98.

Pursuant to the waiver in the notice entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications Filed After June 30, 2003" published on August 5, 2003 in 1273 OG 55, copies of the U.S. Patents cited below are not enclosed. However, copies will be provided upon request.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(d) after a Notice of Appeal. The Commissioner is authorized to charge \$180.00, the fee set

U.S.S.N.: 09/709,045
Filed: November 10, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

forth under 37 CFR § 1.17(p), to Account No. 50-3129. It is believed that no additional fee is required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-3129.

U.S. Patents

| <u>Number</u> | <u>Issue Date</u> | <u>Patentee</u> | <u>Class/Subclass</u> |
|---------------|-------------------|-----------------|-----------------------|
| 5,359,037 | 10-25-1994 | Wallach | 530/389.100 |
| 6,232,446 | 05-15-2001 | Wallach | 424/130.100 |
| 6,982,089 | 01-03-2006 | Tobinick | 424/400 |
| 7,238,776 | 07-03-2007 | Hauptmann | 435/069.100 |

Foreign Documents

| <u>Number</u> | <u>Publication Date</u> | <u>Patentee</u> | <u>Country</u> |
|------------------------|-------------------------|------------------------|----------------|
| 6 296860 (Abstract) | 10-25-1994 | Asahi Med. Co. Ltd. | JP |
| WO 97/014964 | 04-24-1997 | Heinrich, et al. | PCT |

Publications

* SUZUKI, "A prospect of anti-cytokine therapy", Igaku no Ayumi, Japan, Ishiyaku Publishers, Inc., 167(5):432-435 (1993).

OLSSON, "Isolation and characterization of a tumor necrosis factor binding protein from urine", *Eur. J. Haematol.*, 42(3):270-275 (1989).

PEETRE, "A tumor necrosis factor binding protein is present in human biological fluids", *Eur. J. Haematol.*, 41(3):414-419 (1988).

U.S.S.N.: 09/709,045
Filed: November 10, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

/ Patrea L. Pabst /

Patrea L. Pabst
Reg. No. 31,284

Dated: April 29, 2008
PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2151 (Telephone)
(404) 879-2160 (Fax)